About 300 reports

Insulin Resistance Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update,...

  • Insulin
  • World

Insulin Drugs Global Market Opportunities And Strategies To 2031: COVID 19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global insulin drugs market as it emerges from the COVID 19 shut down. Description: Where is the largest and fastest...

  • Insulin
  • World
  • Diabetes Prevalence
  • Gross Domestic Product

The Saudi Arabian diabetes devices market has been estimated at USD 643 million in 2020, registering a CAGR of more than 4% during the forecast period from 2021 to 2026. Diabetes care devices are the devices used to monitor glucose levels in the blood. The main types of diabetes care devices include glucose monitoring devices and management...

  • Insulin Delivery
  • Insulin
  • Saudi Arabia
  • Diabetes Prevalence
  • Health Expenditure

China’s demand for Insulin has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...

  • Insulin
  • China
  • Industrial Production
  • Labour Force

Insulin Resistance (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Drugs in Development, 2021, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape. Insulin resistance...

  • Pharmaceutical
  • Insulin
  • World

Diabetes is a chronic, life-threatening disease with no known cure. While Type 1 diabetes is caused by an immune system malfunction, Type-2 diabetes is linked to leading a sedentary lifestyle, which results in the development of inherent resistance to insulin. The factors that have driven the number of reported cases of diabetes can be segmented...

  • Insulin
  • Europe
  • Diabetes Prevalence
  • Mortality Rate

Major players in the insulin pens, syringes, pumps, and injectors devices and equipment market are Novo Nordisk A/S, Eli Lilly and Company, Medtronic plc, Abbott, Insulet Corporation, Sanofi, Roche F. Hoffmann-La Roche Ltd, Becton, Animas Corporation, and Ypsomed Holding AG. The global insulin pens, syringes, pumps and injectors market...

  • Insulin Delivery
  • Insulin
  • World
  • United States
  • APAC
  • Diabetes Prevalence

The Global Insulin Syringes Market size is expected to reach $2.1 billion by 2027, rising at a market growth of 4.5% CAGR during the forecast period. Insulin controls the body’s fat and glucose metabolism. It is a peptide hormone that is released by beta cells in the islets of Langerhans in the pancreas and aids in glucose metabolism...

  • Insulin Delivery
  • Insulin
  • Diabetes
  • World
  • Drug Approval
  • Diabetes Prevalence

Major players in the market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, NovoRapid/Novolog, Actrapid, Admelog, Novolin/Actrapid/Insulatard, Ryzodeg, Sanofi, Soliqua/Suliqua, Toujeo, Tresiba and Xultophy. The global insulin drugs market is expected to grow from $28.82 in billion 2021 to $32.51...

  • Insulin
  • Diabetes
  • World
  • United States
  • Middle East
  • India
  • APAC
  • United Kingdom
  • Diabetes Prevalence
  • Labour Utilisation

Smart Insulin or Glucose Responsive Insulin market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Smart Insulin or Glucose Responsive Insulin Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Smart Insulin...

  • Insulin
  • World

Major players in the insulin drugs market are Apidra, Eli Lilly, Humalog, Humulin, Insuman, Lantus, Levemir, Novo Nordisk, Novomix, and NovoRapid/Novolog. The global insulin drugs market is expected to grow from $25.88 in billion 2020 to $27.2 billion in 2021 at a compound annual growth rate (CAGR) of 5.1%.The growth is mainly due to...

  • Insulin
  • Diabetes
  • World
  • United States
  • APAC
  • United Kingdom
  • Diabetes Prevalence
  • Labour Utilisation

Human Recombinant Insulin market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Human Recombinant Insulin Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Human Recombinant Insulin types, applications. Further,...

  • Protein Therapy
  • Insulin
  • World

Insulin Management System market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Insulin Management System Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Insulin Management System types, applications. Further,...

  • Insulin
  • World

Insulin Resistance - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H2 2020, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape. Insulin resistance (IR) is a condition...

  • Insulin
  • World

The Human Insulin Drugs Market is expected to register a CAGR of 4.19% during the forecast period of 2020-2025 and is estimated to reach USD 29.9 billion by 2025. Diabetes is generally considered as a lifestyle-related disease. Over time, incidences of the disease have increased outrageously, with the increase in population around the world....

  • Insulin
  • Recombinant Insulin
  • Diabetes Prevalence
  • Drug Approval

The Global Rapid Acting Insulin Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 5.6% CAGR during the forecast period. Rapid-acting insulin is considered as one of the quickest acting insulin that shows the action of working just after the 15 minutes of its application. Insulin’s activation is expected to...

  • Insulin
  • World

Major players in the insulin pens, syringes, pumps and injectors market are Novo Nordisk A/S (Denmark), Eli Lilly and Company, Medtronic plc (Ireland), Abbott, and Insulet Corporation (US). The global insulin pens, syringes, pumps and injectors market is expected to grow from $18.83 billion in 2020 to $19.26 billion in 2021 at a compound...

  • Insulin Delivery
  • Insulin
  • World
  • United States
  • Diabetes Prevalence

Major players in the smart insulin pens market are Companion Medical, Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co. Ltd., Emperra GmbH E-Health Technologies, Digital Medics Pvt Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Jiangsu Delfu medical device Co. Ltd., and Bigfoot biomedical. The global smart insulin pens market...

  • Insulin Delivery
  • Insulin
  • United States
  • APAC
  • Medical Technology Density

Abstract: - Global Insulin Storage Devices Market to Reach $1.1 Billion by 2027 - Amid the COVID-19 crisis, the global market for Insulin Storage Devices estimated at US$735 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 6.6% over the analysis period...

  • Insulin
  • World
  • China
  • United States

Rapid Acting Insulin Market by Product Type (Insulin Lispro, Insulin Aspart, and Insulin Glulisine), Indication (Type 1 Diabetes and Type 2 Diabetes), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2020–2027 The...

  • Insulin
  • World
  • Diabetes Prevalence
  • Cause-Specific Mortality Rate

2021 Insulin Market - Size, Share, COVID Impact Analysis and Forecast to 2027 2021 Insulin Market - Size, Share, COVID Impact Analysis and Forecast to 2027 – is comprehensive research with in-depth data and contemporary analysis of Insulin Market at a global, regional and key country level, split by different sub-segments...

  • Insulin
  • World
  • APAC
  • Disposable Income

Human Recombinant Insulin Market Report Overview Human Recombinant Insulin market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Human Recombinant Insulin market types and applications. It is a focused study on Human Recombinant Insulin market...

  • Protein Therapy
  • Insulin
  • World
  • APAC
  • Health Provider Density

Abstract: - Global Polycystic Ovary Syndrome (PCOS) Treatment Market to Reach $4.6 Billion by 2027 - Amid the COVID-19 crisis, the global market for Polycystic Ovary Syndrome (PCOS) Treatment estimated at US$3.6 Billion in the year 2020, is projected to reach a revised size of US$4.6 Billion by 2027, growing at a CAGR...

  • Insulin
  • Contraceptive
  • World
  • China
  • United States

The global human insulin market reached a value of US$ 40.4 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 63.5 Billion by 2027, exhibiting a CAGR of 7.11% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence...

  • Recombinant Insulin
  • Insulin
  • In-Store Retail
  • World
  • Overweight Prevalence
  • Medicine Use

The Global Insulin Storage Devices Market size is expected to reach $1.1 billion by 2026, rising at a market growth of 8.9% CAGR during the forecast period. Insulin is a naturally occurring, glucose-lowering hormone that is used by many diabetic people to regulate their blood sugar. For people with type 1 diabetes, supplementary insulin compensates...

  • Insulin
  • World
  • Asia
  • APAC

Next Generation Diabetes Therapy and Drug Delivery Market By Product (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas), By Demographic (Adult Population (>14years), Child Population (14years)), By Indication (Type 1 Diabetes, Type 2 Diabetes), By End User (Diagnostic/Clinics, ICUs, Home Healthcare):...

  • Diabetes
  • Drug Delivery
  • Insulin
  • Insulin Delivery
  • World
  • Disposable Income
  • Diabetes Incidence

INTRODUCTION Chronic diseases, such as diabetes, cardiovascular disorders, neurological disorders, autoimmune disorders and various types of cancer, are known to be the leading causes of death and disability across the world. The clinical conditions associated with these diseases affect patients’ overall quality of life....

  • Drug Delivery
  • Injectable Delivery
  • Insulin
  • World
  • Europe
  • APAC
  • North America
  • Number Of Enterprises
  • Chronic Disease Prevalence

Insulin Receptor (IR or CD220 or INSR or EC 2.7.10.1) - Drugs in Development, 2021 Summary Insulin Receptor (IR or CD220 or INSR or EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis on Insulin Receptor (IR or CD220 or INSR or EC 2.7.10.1) targeted pipeline therapeutics. The report...

  • Insulin
  • Research And Development
  • Drug Development
  • World

Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drugs in Development, 2021 Summary Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis on Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1)...

  • Insulin
  • Research And Development
  • Drug Development
  • World

Cells Expressing Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drugs in Development, 2021 Summary Cells Expressing Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) - Drugs in Development, 2021 provides in depth analysis on Cells Expressing Insulin Like...

  • Insulin
  • Research And Development
  • Drug Development
  • World